AtriCure (Nasdaq: ATRC) announced today that it launched its cryoXT cryoablation device for managing post-operative pain after amputation.
Mason, Ohio–based AtriCure says more than 185,000 amputations occur in the U.S. each year, with approximately 60% of patients experiencing residual limb pain and up to 85% reporting phantom limb pain.
To combat this, the company developed its cryoICE platform to use a unique freezing method to block nerve pain signals. Introducing its cryoXT device gives physicians access to a next-generation tool that brings this approach to post-amputation pain management.
cryoXT holds FDA 510(k) clearance to temporarily block pain following amputation by ablating peripheral nerves. It builds upon the proven safety and efficacy of the company’s cryoSphere devices. The device features a newly designed tip with multi-surface freezing technology to precisely target large-diameter exposed peripheral nerves.
Dr. Bryan Houseman, an orthopedic surgeon at the Elliot Hospital in Manchester, New Hampshire, said the device allows surgeons to address pain at the time of surgery effectively. This, Houseman says, improves both recovery and quality of life.
“The launch of the cryoXT device reflects our commitment to bringing meaningful, differentiated solutions to patients and providers in a significant and underserved segment of the surgical market,” said Michael Carrel, president and CEO of AtriCure. “We’re addressing a clear gap in post-amputation care by helping more patients successfully manage pain. It’s a powerful combination of doing good and expanding AtriCure’s growth pathways.”
